People with a BMI between 30 and 35 and one health problem linked to their size could also be prescribed the drug. It is for this reason that NICE approved the jab, alongside a calorie-reduced diet and increased exercise, for adults who have at least one weight-related condition - such as pre-diabetes, high blood pressure or sleep apnoea - and a BMI of 35 or higher. Trials found those on it lost around 12 per cent of their body weight - and slashed their chances of type 2 diabetes by more than half.Īs well as taking the drug, made by Denmark-based Novo Nordisk, participants ate 500 calories fewer than they burned each day - so they had a calorie deficit - and were told to exercise for two-and-a-half hours per week. It does this by mimicking the hormone glucagon-like peptide-1 (GLP-1), which is released after eating. Semaglutide - the key ingredient in the jab - works by hijacking the brain to suppress appetite and reduce calorie intake, resulting in substantial weight loss.
The National Institute for Health and Care Excellence (NICE) yesterday concluded that Wegovy could be given to adults in England on the NHS. Health Secretary Steve Barclay hopes the approach will tackle Britain's obesity epidemic without turning to 'nanny state measures'. Health leaders are planning to make pharma giants bid for 'multi-billion-pound contracts' to provide the treatments, according to The Times. Health Secretary Steve Barclay hopes the approach will tackle Britain's obesity epidemic without turning to 'nanny state measures'
0 kommentar(er)
